stem cell TREATMENT RESULTS
We investigate the use of autologous adipose derived stromal vascular fraction (SVF), which contains adipocytes, perivascular, and hematopoietic stem cells. This work is carefully controlled and conducted under U.S. Institutional Review Board IRB approved protocols as evidence from adequate, well-controlled clinical trials and meeting regulatory standards for such promising therapies throughout our affiliate centers around the world. Patient data is collected and follow ups conducted every 3 months to determine safety and efficacy of the cell surgical procedure.
See Our Journey
Together with our contractual Cell Surgical Institute as a clinical research organization has accumulated Safety and Efficacy data for over 23500 selected personalized surgical procedures performed under IRB in last 10 years without a single infection caused by adulterated processing of SVF. (All published papers are available at request to :Our Email
Clinically, based on our vast experience with patients, we’ve learned that the state of the injury is probably the most important determinant for success in treatment.
The Surgical Network set out to investigate the use of SVF for regenerative purposes, with an initial primary objective of evaluating safety (adverse events) in 1524 patients. Secondarily, this Safety Data Paper reports on efficacy. This study population accounts for 1698 overall SVF deployments, 1477 of which were intravenous.
Advancements in Mesenchymal Stem Cell (MSC) research are shedding light on how these stem cells may someday be used in various clinical applications such as immunomodulatory therapies (i.e., prevention of graft-versus-host disease - when the transplanted donor cells attack the patient's body, or treatment of Crohn’s disease) and in cell replacement therapies for Mesenchymal tissues such as bone and cartilage
We are proud to have published one of the largest safety data papers on the use of Autologous Stromal Vascular Fraction (SVF) to date, including intravenous infusions. Several Research Papers on below findings, published in reputable Int’l Medical Journals, are available at your request for further information. See our clinical work Scroll up
SAFETY OUTCOME
Over (600) Physicians trained in Techniques
Over (7000) cases completed for various indications
Delivery includes IV, intrathecal, IM and IA
Occasional spinal headache from intrathecal, resolved after (24-72) hours
Several patients reported headache at time of IV injection, with elevates pulse/BP, resolved in about 15 minutes
(1) skin infection at site of liposuction, resolved with antibiotics
(2) possible complications from intravitreal injections, treatments suspended
(0) patient death
The clinical benefits of such cellular therapies conducted under adequate and well-controlled clinical trials, are safe and effective for their intended uses and empirical data are therefore necessary to document safety.